北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 泌尿外科  > 期刊论文
学科主题: 泌尿外科学
题名:
雌激素治疗激素难治性前列腺癌的疗效观察
其他题名: Clinical study of diethylstilbestrol in hormone refractory prostate cancer
作者: 王建伟; 周利群; 纪世祺; 宋刚; 李学松; 何志嵩
关键词: 前列腺肿瘤 ; 雌激素 ; 己烯雌酚 ; Prostatic neoplasms ; Estrogen ; Diethylstilbestrol
刊名: 中华医学杂志
发表日期: 2011
DOI: 10.3760/cma.j.issn.0376-2491.2011.32.005
卷: 91, 期:32, 页:2247-2249
收录类别: 中国科技核心期刊 ; 中文核心期刊 ; CSCD
文章类型: Journal Article
摘要: 目的 观察雌激素治疗激素难治性前列腺痛(HRPC)的临床效果及不良反应.方法 收集北京大学泌尿外科研究所32例激素难治性前列腺癌患者资料,治疗经过每天口服己烯雌酚2 mg,观察服药后血清前列腺特异抗原(PSA)变化,疾病进展时间,患者总体生存率、疾病特异生存率并观察药物毒副作用.结果 29例前列腺癌患者资料完整,平均用药时间(8.6±0.9)个月,PSA反应(PSA降低>50%)8例(27.5%),PSA稳定(PSA降低<50%,或PSA增高<25%)7例(24.1%);PSA进展(PSA增高>25%)14例(48.3%).总体中位疾病进展时间4个月(1~12个月).PSA反应患者中位疾病进展时间6个月(5~12个月).总体生存率为48.3%,疾病特异生存率为55.2%.主要不良反应为乳房胀痛硬结10例(34.5%);深静脉血栓3例(10.3%).结论 每天口服2 mg己烯雌酚治疗激素难治性前列腺癌可使27.5%的患者PSA降低>50%,24.1%患者PSA稳定,中位疾病进展时间4个月,雌激素治疗激素难治性前列腺癌效果肯定. Objective To summarize the clinical outcome and adverse events of estrogen therapy for hormone refractory prostate cancer.Methods A total of 32 patients with hormone refractory prostate cancer received diethylstilbestrol (DES) 2 mg daily at our institute.The data of PSA (prostate-specific antigen)change, time to progression, overall survival rate, disease-specific survival rate and adverse events were collected and analyzed.Results The data of 29 patients were complete.The mean duration of DES dosing was 8.6 ±0.9 months.Among them, 8 (27.5% ) patients achieved a PSA response with a 50% decrement of PSA or more.Seven (24.1% ) patients had a stable level of PSA(50% < PSA < 125% ) while 14 of 29 (48.3% ) maintained a PSA progression with a 25% increment of PSA or more.The overall median time to progression was 4 ( 1 - 12) months.And the median time to progression was 6 (5 - 12) months in the PSA response group.The overall survival rate was 48.3% and disease-specific survival rate 55.2%.The main adverse events were gynecomastia ( 10/29, 34.5% ) and deep vein thrombosis ( 3/29, 10.3% ).Conclusion When used for the treatment of hormone refractory prostate cancer, dethylstilbestrol at a daily dose of 2 mg can achieve a PSA response in 27.5% patients and a PSA stability in 24.1% patients.And the median time to progression is 4 months.Estrogen is efficacious for the patients with hormone refractory prostate cancer.
语种: 中文
原文出处: 查看原文
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/45432
Appears in Collections:北京大学第一临床医学院_泌尿外科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 北京大学泌尿外科研究所,北京大学第一医院泌尿外科,100034

Recommended Citation:
王建伟,周利群,纪世祺,等. 雌激素治疗激素难治性前列腺癌的疗效观察[J]. 中华医学杂志,2011,91(32):2247-2249.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[王建伟]'s Articles
[周利群]'s Articles
[纪世祺]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[王建伟]‘s Articles
[周利群]‘s Articles
[纪世祺]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2018  北京大学医学部 - Feedback
Powered by CSpace